Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07244419 · ClinicalTrials.gov registry record · Early Phase 1
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
A Early Phase 1 study of Hematopoietic Stem Cell Transplantation and Graft Failure, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07244419 is a Early Phase 1 study of Hematopoietic Stem Cell Transplantation and Graft Failure that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 20 participants, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07244419, a Early Phase 1 study of Hematopoietic Stem Cell Transplantation and Graft Failure, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
Conditions Studied
Interventions
- DRUG Emapalumab 3 mg/kg
- DRUG Emapalumab 10 mg/kg
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2029-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07244419
The ClinicalTrials.gov registry entry for NCT07244419 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Emapalumab 3 mg/kg is the first listed.
NCT07244419 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07244419 about?
NCT07244419 is a clinical study titled "Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients". The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechan...
What is the current status of trial NCT07244419?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-07. Estimated completion is 2029-08.
What conditions does trial NCT07244419 study?
This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplantation, Graft Failure.
What interventions are being tested in trial NCT07244419?
The interventions under investigation include: Emapalumab 3 mg/kg (DRUG), Emapalumab 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT07244419?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07244419 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 1
-
Employment Support After Hematopoietic Stem Cell Transplantation
RECRUITING · NA
-
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
RECRUITING · Phase 2
-
Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopoietic Stem Cell Transplant
RECRUITING
-
Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
RECRUITING
-
Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.